Congress trades
GSK plc (GSK)
Free on iOS and Android.
About GSK plc
from the company's filings and listing, as of Oct 25, 2026- Exchange
- NYSE
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Chief executive
- Luke Victor Miels
- Employees
- 66,841
- Listed since
- Mar 28, 1980
- Market value
- $101.7B
- Price to earnings (12 mo)
- 15.8
- Net income per share (12 mo)
- $3.22in US dollars, from price and P/E
- Dividend yield
- 3.59%
Company news
1 article · newest first| Headline | Source | Date |
|---|---|---|
| GSK partners with Viola Davis on shingles education campaign for adults 50+Davis discusses her own shingles experience for the first time, encouraging adults 50 and older to talk with their doctors. | Company release | Oct 8, 2026 |
Written by GetSignal with AI from the company's own SEC filings and press releases; each article links to its source. Not investment advice. Company news from every company we cover
Earnings
6 reported quarters · next on Oct 28, 2026| Quarter | EPS | EPS expected | Revenue | Revenue expected | Result |
|---|---|---|---|---|---|
| Q2 FY2026reported Jul 28, 2026 | $1.36 | $1.27 | $11.2B | $11.0B | EPS beatRevenue in line |
| Q1 FY2026reported Apr 29, 2026 | $1.24 | $1.16 | $10.3B | $10.2B | EPS beatRevenue in line |
| Q4 FY2025reported Feb 4, 2026 | $0.68 | $0.64 | $11.8B | $11.4B | EPS beatRevenue beat |
| Q3 FY2025reported Oct 29, 2025 | $1.48 | $1.26 | $11.3B | $11.0B | EPS beatRevenue beat |
| Q2 FY2025reported Jul 30, 2025 | $1.23 | $1.12 | $10.6B | $10.5B | EPS beatRevenue in line |
| Q1 FY2025reported Apr 30, 2025 | $1.13 | $1.08 | $10.0B | $9.7B | EPS beatRevenue beat |
Actual against the consensus estimate at the time. A flag marks a beat or a miss of more than 1.5% either way; inside that band the quarter is in line. A flag reads n/a only when a number is missing. Quarterly EPS is the figure set against the consensus, usually adjusted, so the quarters need not add up to the 12-month net income per share above. An estimate is a forecast made by analysts, not a company target.
Institutional holders
13F positions as of Jun 30, 2026| Holder | Value | Shares | Shares vs prior qtr | % of shares out |
|---|---|---|---|---|
| FMR LLC | $3.4B | 64,961,641 | -4.0% | 3.24% |
| Dodge & Cox | $2.5B | 48,197,514 | -17.8% | 2.40% |
| Fisher Asset Management, LLC | $1.9B | 35,722,792 | +3.5% | 1.78% |
| Primecap Management Co | $1.3B | 25,182,068 | -0.1% | 1.25% |
| Wellington Management Group LLP | $597.4M | 11,396,249 | -2.7% | 0.57% |
| JTC Employer Solutions Trustee Ltd | $450.3M | 8,592,987 | -5.0% | 0.43% |
| Morgan Stanley | $401.4M | 7,657,562 | -30.6% | 0.38% |
| Royal Bank of Canada | $397.8M | 7,588,928 | +1.1% | 0.38% |
| T. Rowe Price Associates, Inc. | $362.9M | 6,923,642 | -5.5% | 0.34% |
| Acadian Asset Management LLC | $349.1M | 6,660,434 | -43.5% | 0.33% |
| Goldman Sachs Group Inc | $334.0M | 6,371,442 | -33.6% | 0.32% |
| State Street Corp | $315.1M | 5,959,115 | -0.7% | 0.30% |
A 13F reports long US equity positions and is filed within 45 days of the quarter end, so these are positions as they stood on Jun 30, 2026. For a manager's whole book see the fund directory. What a 13F covers and leaves out is explained in our guide to Form 13F.
GetSignal watches Form 4 and STOCK Act filings and pushes each one to your phone as it is published, with the history behind it. Free on iOS and Android.
Congress trades in GSK
20 disclosures of 62 on record · median 33d of the 45 allowedSince the trade: the stock's move from the trade date to the latest close we hold (figures as of Oct 25, 2026), not the member's result. Not investment advice.
| Member | Type | Action | Amount disclosed | Stock since the trade | Trade date | Disclosed | Delay |
|---|---|---|---|---|---|---|---|
| Lisa C. McClainSpouse | Stock | Purchase | $1,001 - $15,000 | +6.6%S&P 500 +13.3% · -6.7 pts vs S&P 500 | Oct 30, 2025 | Nov 21, 2025 | 22d |
| Lisa C. McClainSpouse | Stock | Sale | $1,001 - $15,000 | +9.1%After the saleS&P 500 +12.3% · -3.2 pts vs S&P 500 | Oct 30, 2025 | Nov 21, 2025 | 22d |
| Lisa C. McClainSpouse | Stock | Sale | $1,001 - $15,000 | +8.3%After the saleS&P 500 +11.4% · -3.1 pts vs S&P 500 | Oct 31, 2025 | Nov 21, 2025 | 21d |
| Val T. HoyleSpouse | Stock | Sale | $1,001 - $15,000 | +25.3%After the saleS&P 500 +14.2% · +11.0 pts vs S&P 500 | Sep 23, 2025 | Oct 10, 2025 | 17d |
| Lisa C. McClainSpouse | Stock | Purchase | $1,001 - $15,000 | +34.7%S&P 500 +20.4% · +14.3 pts vs S&P 500 | Aug 4, 2025 | Sep 12, 2025 | 39d |
| Val T. HoyleSpouse | Stock | Purchase | $1,001 - $15,000 | +50.6%S&P 500 +29.2% · +21.5 pts vs S&P 500 | Nov 18, 2024 | Sep 12, 2025 | 298d |
| Robert B. Aderholt | Stock | Sale | $1,001 - $15,000 | +35.5%After the saleS&P 500 +19.3% · +16.2 pts vs S&P 500 | Jul 28, 2025 | Sep 10, 2025 | 44d |
| Lisa C. McClainSpouse | Stock | Purchase | $1,001 - $15,000 | +27.8%S&P 500 +27.2% · +0.6 pts vs S&P 500 | Jun 17, 2025 | Aug 13, 2025 | 57d |
| Lisa C. McClainSpouse | Stock | Sale | $1,001 - $15,000 | +31.2%After the saleS&P 500 +24.9% · +6.3 pts vs S&P 500 | Jun 24, 2025 | Aug 13, 2025 | 50d |
| Bruce Westerman | Stock | Sale | $1,001 - $15,000 | +39.2%After the saleS&P 500 +47.9% · -8.7 pts vs S&P 500 | Apr 21, 2025 | May 12, 2025 | 21d |
| Bruce Westerman | Stock | Purchase | $1,001 - $15,000 | +33.7%S&P 500 +30.1% · +3.6 pts vs S&P 500 | Mar 3, 2025 | Apr 16, 2025 | 44d |
| Marjorie Taylor Greene | Stock | Purchase | $1,001 - $15,000 | +48.6%S&P 500 +27.2% · +21.4 pts vs S&P 500 | Nov 25, 2024 | Nov 27, 2024 | 2d |
| Tommy TubervilleJoint | Stock | Sale (Full) | $1,001 - $15,000 | +38.7%After the saleS&P 500 +74.4% · -35.7 pts vs S&P 500 | Oct 16, 2023 | Nov 16, 2023 | 31d |
| Daniel S. Goldman | Stock | Sale | $15,001 - $50,000 | +49.9%After the saleS&P 500 +72.9% · -23.0 pts vs S&P 500 | Jul 10, 2023 | Aug 13, 2023 | 34d |
| Tommy TubervilleJoint | Stock | Purchase | $1,001 - $15,000 | +41.2%S&P 500 +85.0% · -43.9 pts vs S&P 500 | Apr 3, 2023 | May 11, 2023 | 38d |
| Virginia FoxxJoint | Stock | Sale | $50,001 - $100,000 | +48.1%After the saleS&P 500 +92.6% · -44.4 pts vs S&P 500 | Mar 1, 2023 | Apr 4, 2023 | 34d |
| Virginia FoxxJoint | Stock | Purchase | $15,001 - $50,000 | +25.1%S&P 500 +83.9% · -58.7 pts vs S&P 500 | Aug 5, 2022 | Sep 8, 2022 | 34d |
| Virginia FoxxJoint | Stock | Purchase | $1,001 - $15,000 | +26.8%S&P 500 +84.7% · -58.0 pts vs S&P 500 | Aug 9, 2022 | Sep 8, 2022 | 30d |
| Virginia FoxxJoint | Stock | Purchase | $15,001 - $50,000 | +32.5%S&P 500 +81.0% · -48.4 pts vs S&P 500 | Aug 10, 2022 | Sep 8, 2022 | 29d |
| Virginia FoxxJoint | Stock | Purchase | $1,001 - $15,000 | +43.9%S&P 500 +76.8% · -32.9 pts vs S&P 500 | Aug 16, 2022 | Sep 8, 2022 | 23d |
Since the trade is an estimate, set beside the S&P 500 over the same window, with the gap between the two in percentage points. The filing carries a band, not a fill, and a sale keeps the stock's sign, so a positive figure after a sale means the stock kept rising after it. An option row carries the underlying stock's move. A row marked n/a is one we hold no figure for.
A delay above 45 days is the gap between the dates on the report; we mark a filing late only after checking it.
"Not captured" means the band or the transaction type on the original report is missing from our data.
"Dates conflict" marks a row whose disclosure is dated before its trade on the record we hold. Both dates are printed as filed, and no since-the-trade figure is computed from them.
Every Congress trade in GSK, filterable by party, chamber, type and account.
Members of Congress reporting a position
3 members · estimate, as of Oct 24, 20263 members report a position (estimated). The largest estimated position is in the $50,001 - $100,000 band.
| Member | Party, chamber | Estimated position | Share of their portfolio |
|---|---|---|---|
| Harriet M. Hageman | Republican · House | $50,001 - $100,000 | 2.6% |
| Lucy McBath | Democrat · House | $15,001 - $50,000 | 0.7% |
| Steve Cohen | Democrat · House | $15,001 - $50,000 | 0.9% |
Estimate, as of Oct 24, 2026. Each position is modelled from the member's disclosed transactions and annual filings: the midpoint of each disclosed band, moved with the stock's price since the trade. It is a rough estimate of a reported position, not a figure from a filing, which is why it is shown as a band. Share of portfolio sets that estimate against the member's whole estimated public-stock portfolio.
Questions
Which members of Congress have traded GSK?
Lisa C. McClain, Val T. Hoyle, Robert B. Aderholt, Bruce Westerman, Marjorie Taylor Greene, Tommy Tuberville and others disclosed GSK transactions in the filings shown here.
Which members of Congress hold GSK?
3 members of Congress report a position in GSK in the estimate we hold as of Oct 24, 2026. The estimated positions belong to Harriet M. Hageman, Lucy McBath and Steve Cohen. The estimate is built from disclosed transactions and annual filings, so it is shown as a band rather than a figure from a filing.
How quickly are GSK trades disclosed?
Congressional disclosures took a median of 33 days, against the 45 the STOCK Act allows.
How to read a STOCK Act filing
WHAT THE FILING ACTUALLY SAYS
Congress rows disclose a value range rather than an exact amount, and the STOCK Act allows up to 45 days to report. Full sourcing and the limits of this data are on the methodology page. A filing is a record of a transaction, not a signal, and nothing here is investment advice.
Data as of Oct 26, 2026.